What is Vivos Therapeutics Inc's share price today?
Vivos Therapeutics Inc (VVOS) share price today is $0.13 as of October 27, 2026 at 1:28 AM IST. The stock touched a day high of $0.13 and a day low of $0.12.What exchange does Vivos Therapeutics Inc stock trade on, and under what ticker symbol?
Vivos Therapeutics Inc stock trades on NASDAQ under the ticker symbol VVOS.What is Vivos Therapeutics Inc's market capitalization?
Vivos Therapeutics Inc's market capitalization is $4.49M as of October 27, 2026 at 1:28 AM IST.What is Vivos Therapeutics Inc's price-to-earnings (P/E) ratio?
Vivos Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.What is Vivos Therapeutics Inc's price-to-book (P/B) ratio?
Vivos Therapeutics Inc's price-to-book (P/B) ratio is 6.86 as of October 26, 2026.Can Indian investors buy Vivos Therapeutics Inc shares?
Yes, You can buy Vivos Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Vivos Therapeutics Inc shares from India?
Indian investors can buy Vivos Therapeutics Inc shares in three steps: 1. Search Vivos Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Vivos Therapeutics Inc shares for Indian investors?
Since Vivos Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Vivos Therapeutics Inc shares via Tickertape?
Indian investors can start investing in Vivos Therapeutics Inc (VVOS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 76.3358 shares at the current price of $0.13.
Key Metrics
Key Metrics
Close price divided by the earnings per share for the trailing twelve months
Close price divided by the book value per share at the end of the most recent quarter
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
Net profit divided by the total revenue for the most recent financial year
Annual dividend per share for the trailing twelve months divided by the close price
Based on 3 analysts reports
Price Upside
+1483.17%
Earnings Growth
+35.14%
Rev. Growth
+24.92%
Company Profile
Company Profile
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
All values in $
All values in $
Revenue Forecast
Revenue Forecast
The next fiscal year's mean estimate implies 24.92% growth, versus a trailing 3-year CAGR of 2.87%.
All values in $ Million
All values in $ Million
Earnings Per Share Forecast
Earnings Per Share Forecast
All values in $
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
| Financial Year | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3.41 | 4.05 | 3.86 | 3.69 | 3.01 | 3.82 | 6.78 | 3.82 | 5.14 | 5.15 |
| Gross Profit | 1.93 | 2.65 | 2.33 | 2.09 | 1.50 | 2.11 | 3.93 | 2.98 | 2.60 | 2.95 |
| Net Income | -3.76 | -1.93 | -2.61 | -2.82 | -3.86 | -5.01 | -5.4 | -6.95 | -7.75 | -5.48 |
| Net Profit Margin | -110.06% | -47.60% | -67.77% | -76.44% | -128.11% | -131.23% | -79.61% | -181.85% | -150.76% | -106.36% |
Peers
Peers & Comparison
Peers & Comparison
HealthcareMedical Devices
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Vivos Therapeutics Inc | - | 6.86 | - |
| Abbott Laboratories | 38.55 | 3.57 | 2.12 |
| Danaher Corporation | 38.16 | 2.95 | 1.32 |
The 12-month consensus target implies 1483.17% growth, versus a trailing 3-year CAGR of -73.21%.